Hepatitis C remains the main etiology of hepatocellular carcinoma among liver transplant recipients in the United States in the direct-acting antiviral era

被引：0
|
作者：
Saberi, B. [1 ]
Hashim, D. [1 ]
Dinani, A. [1 ]
Asgharpour, A. [1 ]
Kushner, T. [1 ]
Tabrizian, P. [1 ]
Schwartz, M. [1 ]
Dieterich, D. [1 ]
Llovet, J. M. [1 ]
Boffetta, P. [1 ]
Friedman, S. L. [1 ]
Gurakar, A. [2 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Johns Hopkins Comprehens Transplant Ctr, Baltimore, MD USA
来源：
TRANSPLANTATION | 2019年 / 103卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P-438
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [1] Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
    Tse, Chung Sang
    Yang, Ju Dong
    Mousa, Omar Y.
    Nelson, Kevin M.
    Pungpapong, Surakit
    Keaveny, Andrew
    Aqel, Bashar A.
    Vargas, Hugo
    Dickson, Rolland C.
    Watt, Kymberly
    Gores, Gregory J.
    Roberts, Lewis R.
    Leise, Michael D.
    TRANSPLANTATION DIRECT, 2021, 7 (01): : E635
  • [2] Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era
    Okumura, Kenji
    Sogawa, Hiroshi
    Samson, David
    Butler, Jonathan
    Veillette, Gregory
    John, Devon
    Diflo, Thomas
    Bodin, Roxana
    Wolf, David C.
    Latifi, Rifat
    Nishida, Seigo
    TRANSPLANTATION PROCEEDINGS, 2022, 54 (07) : 1834 - 1838
  • [3] Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis C
    Tse, Chung Sang
    Yang, Judong
    Mousa, Omar
    Pungpapong, Surakit
    Keaveny, Andrew
    Nelson, Kevin
    Bashar, Aqel
    Dickson, Rolland
    Vargas, Hugo E.
    Gores, Gregory
    Roberts, Lewis
    Leise, Michael
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E571 - E571
  • [4] Therapy With Direct-Acting Antiviral Agents for Hepatitis C in Liver Transplant Recipients
    Nogueras Lopez, F.
    Lopez Garrido, A.
    Ortega Suazo, E. J.
    Vadillo Galles, F.
    Valverde Lopez, F.
    Espinosa Aguilar, M. D.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (02) : 631 - 633
  • [5] Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
    Akamatsu, Nobuhisa
    Togashi, Junichi
    Hasegawa, Kiyoshi
    Kokudo, Norihiro
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S598 - S602
  • [6] IMPACT OF DIRECT-ACTING ANTIVIRAL AGENTS ON LIVER TRANSPLANT OUTCOMES AMONG BLACK RECIPIENTS IN THE UNITED STATES
    Ochoa-Allemant, Pedro
    Ezaz, Ghideon
    HEPATOLOGY, 2021, 74 : 915A - 915A
  • [7] Hepatocellular carcinoma after direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus
    Calca, Rita
    Jorge, Cristina
    Lebre, Luis
    Cacheira, Eunice
    Querido, Sara
    Nascimento, Celia
    Adragao, Teresa
    Bruges, Margarida
    Weigert, Andre
    Machado, Domingos
    NEFROLOGIA, 2020, 40 (06): : 675 - 676
  • [8] Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents
    Suraweera, Duminda
    Saab, Elena G.
    Tong, Myron J.
    Saab, Sammy
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2016, 14 (03) : 243 - 251
  • [9] Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
    Lim, Nicholas
    Singh, Dupinder
    Jackson, Scott
    Lake, John R.
    GASTROINTESTINAL TUMORS, 2020, 7 (04) : 134 - 143
  • [10] Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era
    Okumura, K.
    Sogawa, H.
    Veillette, G.
    John, D.
    Diflo, T.
    Bodin, R.
    Wolf, D. C.
    Nishida, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 768 - 769
12345